Navigation Links
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
Date:7/27/2009

- Management to discuss second quarter financial results -

LAVAL, QC, July 27 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 7, 2009 at 8:30 a.m. (ET) to discuss its second quarter 2009 financial results. Labopharm will report its second quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labophar
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
2. Labopharm amends debt facility agreement with Hercules
3. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
4. Labopharm Reports Results for First Quarter Fiscal 2009
5. Labopharm announces details for first quarter results conference call and annual meeting
6. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
7. Labopharm to present at Cowen 29th Annual Health Care Conference
8. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
9. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
10. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
11. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... 2015 SB 277 (CA Legislature, bit.ly/1Q0P8OY) ... to attend public or private school. SB277 cleared three ... the Appropriations Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). ... , “We believe that this bill affects the ... than it will (the) affect public health of California.. ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Miriam Wirski as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Miriam with this prestigious honor,” said NAPW President Star ...
(Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
(Date:6/1/2015)... The National Association of Professional Women ... (C), First Sergeant A Co., 15BSB , as a ... Circle. She is recognized with this prestigious distinction for ... networking organization exclusively for professional women, boasting more than ... “I'm pleased to recognize Sergeant Cornett with this important ...
Breaking Medicine News(10 mins):Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2
... RIVERSIDE, California and NUREMBERG, Germany, June ... United States Food and Drug,Administration (FDA) has given 510k ... the Ziehm Vision(R) RFD, for marketing and,sales within the ... and interventional radiology, the Ziehm Vision RFD,mobile C-arm combines ...
... M.A.Z.E. ... is dedicated to helping parents save money and the giveaway is another chance for parents ... ... education with M.A.Z.E. Cord Blood Laboratories. M.A.Z.E. is offering a drawing to win a ...
... LONDON, June 10 ThirdForce, the UK,s leading,e-learning ... one of,the most respected care home companies in the UK, ... for Life,e-learning to enhance Barchester,s quality provision of care and ... a key component to the success of the,Barchester business; a ...
... percent of the 5.5 billion kilograms of toxic pollutant ... can be traced to just 30 substances from 15 ... according to the latest tri-national pollution report from the ... 2005, released today,represents the most complete picture of pollution ...
... difference to Ontario,s community mental health system? According to ... the answer is yes. Ontarians now have access to ... also highlights the system,s limited resources to serve all ... for Addiction and Mental Health (CAMH),s Dr. Paula Goering, ...
... New Tissue Dissection System Used by Italian Surgeons in Oncology ... PALO ALTO, Calif., June 10 PEAK Surgical, Inc., today ... surgeons in the European Union, where the innovative tissue dissection ... , Dr. Raul Pellini and Prof. Giuseppe Spriano, ear, nose ...
Cached Medicine News:Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:M.A.Z.E. Cord Blood Laboratories Offers Expectant Parents The Chance To Win A $500 Savings Bond 2Health News:Barchester Healthcare Gains Skills for Life With ThirdForce 2Health News:Barchester Healthcare Gains Skills for Life With ThirdForce 3Health News:Latest trinational report presents most complete picture of North American industrial pollution 2Health News:Latest trinational report presents most complete picture of North American industrial pollution 3Health News:Evaluation shows $167 million investment improves community mental health system, but many still in need 2Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 2Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 3Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 4
(Date:6/2/2015)... MADRID , June 2, 2015 /PRNewswire/ ...   10503), vorgestellt auf dem Jahrestreffen der ... PharmaMar teilt mit, dass Janssen Research ... multizentrischen Phase-3-Studie SAR3007 bekannt gegeben hat, ... (progression-free survival, PFS) mit Trabectedin (YONDELIS ® ...
(Date:6/1/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... a Phase 1b study to evaluate the safety ... immunotherapy, in combination with Roche,s investigational anti-PDL1 therapy, ... triple-negative breast cancer and colorectal cancer with liver ... oncolytic immunotherapy designed to selectively replicate in tumors ...
(Date:6/1/2015)... June 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the three months ... herein are in Canadian dollars unless otherwise stated. ... business strategies despite its limited financial resources," stated ...
Breaking Medicine Technology:PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
... (Nasdaq: GNTA ) today announced financial results and progress,for ... noted,significant recent milestones, including:, -- ... -- New oral product, G4544, completes initial Phase ... -- Tesetaxel, a leading oral taxane, becomes new ...
... Committee Recommends FDA Approve Novel Anesthesia Drug to Reverse Muscle ... ... Schering-Plough,(NYSE: SGP ) today announced that the U.S. ... Support has recommended,sugammadex for approval. After reviewing data on the ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 2FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: